| Does Anavex's Alzheimer's Drug Actually Confer Benefit? |
Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug may offer years of extra mental lucidity and greater self-sufficiency among Alzheimer's patients. The EU's approval of Blarcamesine could increase Anavex's market value from $800 million to $8 billion. |
seekingalpha.com |
2025-05-16 00:49:20 |
Czytaj oryginał (ang.) |
| The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade) |
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to European Medicines Agency approval. The benefits of blarcamesine may increase over time due to reduced oxidative stress, though side effects like diziness and confusion may occur. Given the lack of effective Alzheimer's treatments, I cautiously recommend buying Anavex stock based on these promising results. |
seekingalpha.com |
2025-05-15 16:21:31 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Participate at Upcoming Healthcare Conferences |
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference |
globenewswire.com |
2025-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript |
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. |
seekingalpha.com |
2025-05-13 13:25:36 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update |
Company to host a webcast today at 8:30 a.m. Eastern Time |
globenewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 |
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET |
globenewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia |
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the successful completion of enrollment in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia (ANAVEX3-71-SZ-001, NCT06245213 ). The study has enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B. |
globenewswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Participate in The Citizens Life Sciences Conference |
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025. |
globenewswire.com |
2025-04-30 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board |
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. |
globenewswire.com |
2025-04-23 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East |
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial” at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East. |
globenewswire.com |
2025-04-21 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease |
ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients. ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference. |
globenewswire.com |
2025-04-05 15:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference |
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:45 PM (ET) on Monday, April 7th, 2025. |
globenewswire.com |
2025-03-31 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference |
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in Boston, MA. |
globenewswire.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex: Looking At Different Statistical Approaches Before EMA Opinion |
Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. |
seekingalpha.com |
2025-02-14 20:02:28 |
Czytaj oryginał (ang.) |
| Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025 |
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031. AVXL has top-line data from the ongoing phase 2 study, using blarcamesine for the treatment of patients with Schizophrenia, expected to be released in 2025. |
seekingalpha.com |
2025-02-12 17:13:29 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript |
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. |
seekingalpha.com |
2025-02-12 11:59:27 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update |
Company to host a webcast t oday at 8:30 a.m. Eastern Time |
globenewswire.com |
2025-02-12 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 |
Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET |
globenewswire.com |
2025-02-05 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio |
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818. |
globenewswire.com |
2025-01-27 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why |
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71. |
zacks.com |
2025-01-24 14:01:08 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 21st |
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025. |
zacks.com |
2025-01-21 13:11:46 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 21st |
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025. |
zacks.com |
2025-01-21 09:45:35 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease |
Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement |
globenewswire.com |
2025-01-15 09:30:00 |
Czytaj oryginał (ang.) |
| New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients |
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients. No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good comparative safety profile and no associated neuroimaging adverse events. |
globenewswire.com |
2025-01-13 09:30:00 |
Czytaj oryginał (ang.) |
| Playing The Odds Of Anavex Alzheimer's Drug Approval |
The EMA has accepted Anavex's Alzheimer's drug Blarcamesine for evaluation, with a decision expected by December 2025. Blarcamesine shows a 92% likelihood of approval by the EMA, yet investors have not priced in this probability. The drug significantly slows cognitive decline by 36%, providing potentially priceless extra years of lucidity for patients. |
seekingalpha.com |
2025-01-12 13:21:52 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL) |
Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2025-01-07 11:51:57 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM – 09:40 AM (Pacific Time). |
globenewswire.com |
2025-01-06 09:30:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? |
Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year. |
zacks.com |
2024-12-31 12:40:34 |
Czytaj oryginał (ang.) |
| All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy |
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-12-30 15:01:08 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision |
Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and functional decline, and an attractive safety profile. The EMA has accepted ANAVEX 2-73's application for early Alzheimer's, potentially leading to a commercial launch in 2025, boosting AVXL's stock. Despite risks like regulatory hurdles, competition, and cash concerns, AVXL's risk-reward profile is appealing for speculative investors as it nears potential approval. |
seekingalpha.com |
2024-12-27 09:30:00 |
Czytaj oryginał (ang.) |
| Short-Squeeze Target Anavex Life Sciences Gains Traction |
Anavex Life Sciences NASDAQ: AVXL is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into the rally. Short interest topped 23% at the end of November and is unlikely to have fallen much since because they spiked to a one-year high, showing a high conviction—plenty of fuel for a short squeeze. |
marketbeat.com |
2024-12-26 09:30:08 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis |
Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. |
seekingalpha.com |
2024-12-24 10:50:05 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript |
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2024 Earnings Call Transcript December 23, 2024 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Clint Tomlinson Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. |
seekingalpha.com |
2024-12-23 12:23:55 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update |
Company to host a webcast t oday at 8:30 a.m. Eastern Time |
globenewswire.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease |
Blarcamesine: Potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement |
globenewswire.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| What To Expect in the Markets This Week |
Markets will trade on shortened hours during the Christmas holiday week, with all markets closed Wednesday for the holiday, and shortened trading hours on Christmas Eve. |
investopedia.com |
2024-12-22 07:25:38 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 |
Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET |
globenewswire.com |
2024-12-16 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference |
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced its upcoming presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial at the J.P. |
globenewswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| North American Morning Briefing : Global Ad Shares -2- |
Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey's General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd - ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET |
https://www.marketscreener.com |
2024-12-09 08:35:38 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 |
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat being held December 4th, 2024 at 3:25pm ET at the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL. |
globenewswire.com |
2024-12-02 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA |
• First marketing authorization submission for blarcamesine NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced the submission of the blarcamesine (ANAVEX®2-73) MAA (Marketing Authorization Application) to the European Medicines Agency (EMA). The MAA submission is for the treatment of Alzheimer's Disease. |
globenewswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal |
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,” in a medical journal with focus on Alzheimer's disease. The publication date is expected around Q4 2024/Q1 2025. |
globenewswire.com |
2024-11-25 09:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario |
Anavex Life Sciences' stock surged on new Alzheimer's trial data, but the data's inconsistency raises concerns, making the company a Hold rating. Despite some promising cognitive results, the lack of statistical significance in functional endpoints and mixed trial performance cast doubt on EU approval chances. Anavex 2-73 shows better safety compared to anti-amyloid antibodies, which may influence EMA's decision given the unmet medical need in Alzheimer's treatment. |
seekingalpha.com |
2024-11-06 07:10:51 |
Czytaj oryginał (ang.) |
| Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 |
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream SIGMAR1 activation. Clinical data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis in people with early Alzheimer's disease (AD). |
globenewswire.com |
2024-10-31 06:00:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia |
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced encouraging preliminary electroencephalography (EEG) biomarker results from the Part A of the ongoing placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia. Part A of the Phase 2 study ANAVEX®3-71-SZ-001 (NCT06245213), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX®3-71 90 mg daily, or oral ANAVEX®3-71 180 mg daily for 10 days. |
globenewswire.com |
2024-10-17 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 |
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City. |
globenewswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript |
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Tom Bishop - BI Research Soumit Roy - Jones Research Clint Tomlinson Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. |
seekingalpha.com |
2024-08-06 16:19:11 |
Czytaj oryginał (ang.) |